Lexeo Therapeutics, Inc. Common Stock
Price Action
Technical Summary
WEAKENINGLexeo Therapeutics, Inc. Common Stock is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 19), showing significant lag compared to the market leaders. Earnings growth of 63% provides fundamental context to the price action. Investors should exercise caution due to high volatility (89% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $6.14 | -5.15% | BELOW |
| 50 SMA | $6.24 | -6.73% | BELOW |
| 100 SMA | $7.22 | -19.37% | BELOW |
| 150 SMA | $7.79 | -25.30% | BELOW |
| 200 SMA | $7.10 | -18.04% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is LXEO in an uptrend right now?
LXEO has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is LXEO overbought or oversold?
LXEO's RSI (14) is 53. The stock is in neutral territory, neither overbought nor oversold.
Is LXEO outperforming the market?
LXEO has a Relative Strength (RS) Rating of 19 out of 99. LXEO is currently lagging the broader market.
Where is LXEO in its 52-week range?
LXEO is trading at $5.82, which is 53% of its 52-week high ($10.99) and 40% above its 52-week low ($2.43).
How volatile is LXEO?
LXEO has a Beta of 1.98 and 52-week volatility of 89%. It's more volatile than the S&P 500 - expect bigger swings.